Updated:
Revolution Medicines
Revolution Medicines is an asset manager based in Redwood City; the Altss profile covers its classification, headquarters, registration, AUM band, and key...
Overview
At Revolution Medicines our mission is to revolutionize treatment for patients with RAS-addicted cancers through targeted medicines.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Redwood City
Corporate office
Redwood City, CA, United States
Sector focus
Frequently asked questions
What is the core scientific platform that distinguishes Revolution Medicines?
The firm’s core approach relies on a proprietary platform for designing tri-complex inhibitors that target the active, GTP-bound form of RAS proteins. This mechanism of action is distinct from earlier attempts that targeted the inactive state. The goal is to suppress oncogenic signaling pathways that drive tumor growth in RAS-addicted cancers.
Which specific cancers and mutations does the company’s pipeline target?
The pipeline is directed primarily at advanced solid tumors harboring RAS mutations. Published clinical programs focus on non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer. The lead candidate, daraxonrasib, targets multiple RAS variants, while earlier programs were designed for specific mutations like KRAS G12C.
What is the firm’s most advanced drug candidate and its development status?
The lead clinical candidate is daraxonrasib (RMC-6236), an oral RAS(ON) multi-selective inhibitor. The molecule is being evaluated in monotherapy and combination trials for advanced solid tumors, representing the firm’s most mature value driver as research translates into potential regulatory outcomes.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: